GLP-1s Beyond Weight Loss: Heart, Kidney & Diabetes Protection

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

GLP-1s Beyond Weight Loss: Heart, Kidney & Diabetes Protection

Ascolta gratuitamente

Vedi i dettagli del titolo

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.

In this episode of HealthNotes with Dr. Bob, Dr. Robert Driver, MD, and producer Dave explore GLP-1 receptor agonists, moving past the media hype to reveal how these medications work beyond weight loss. They explore how GLP-1s naturally interact with our biochemistry, silence internal "food noise," reduce cardiovascular and kidney risks, and curb alcohol cravings. Whether you are considering GLP-1 therapy or simply aiming to optimize your metabolic health and longevity, this episode delivers practical, evidence-based medical clarity.Key TakeawaysMultiple Mechanisms at Play: GLP-1 medications work centrally to quiet "food noise" and mental chatter while slowing gastric emptying, making caloric adherence significantly easier. Mitigating Lean Mass Loss: Weight loss in any form causes some loss of lean tissue. To protect muscle mass on GLP-1 therapy, patients must prioritize hitting daily protein targets and engage in routine resistance training. Proactive Metabolic Health: Intervening with low-dose GLP-1s early in the metabolic health spectrum prevents damaging blood sugar spikes (hyperglycemia) that erode microvascular structures in the heart, kidneys, eyes, and brain long before Type 2 Diabetes is diagnosed. Cardiovascular & Kidney Protection: Major clinical trials demonstrate that GLP-1 therapies decrease major adverse cardiovascular events (MACE) by 20% and slow kidney disease progression, with significant benefits occurring independently of weight loss. Individualized, Flexible Dosing: Clinical dosing should adapt to patient response rather than rigid calendar schedules, mitigating GI side effects while finding the minimum effective dose. Key Moments & Timestamps0:00 Cold Open: How High Blood Sugar Damages Your Body0:38 Welcome Back & Today's Topic: GLP-1 Medications0:57 What Are GLP-1s? Semaglutide, Tirzepatide & Retatrutide Explained2:20 How GLP-1s Actually Help You Lose Weight3:47 Side Effects & Flexible Dosing6:28 Preserving Muscle: Protein, Resistance Training & the Bariatric Surgery Comparison9:03 Food Noise & Changing Your Relationship with Eating11:36 Beyond Weight Loss: The Diabetes & Metabolic Health Connection14:07 Why Blood Sugar Control Matters: Preventing Long-Term Organ Damage16:33 Cardiovascular Protection: The SELECT Trial19:00 Why Won't Insurance Cover It? FDA Indications Explained21:04 Kidney Protection: The FLOW Trial23:34 Sleep Apnea & Alcohol Use: Surprising Benefits27:07 Addressing Common Fears: "Is This Natural?"31:23 Do You Need to Stay on GLP-1s Forever?35:33 Wrap-Up & OutroConnect with Dr. BobVisit Dr. Driver at Spartan Medical Associates: https://spartanmedicalassociates.com/Have a question for the show? Email us at: contact@healthnotes.netSOURCE LINKSCardiovascular:SELECT: Semaglutide Reduces Risk of MACE in Adults With Overweight or Obesity (ACC)Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements — prespecified SELECT analysis (The Lancet)Alcohol use disorder:Once-weekly semaglutide versus placebo in alcohol use disorder + comorbid obesity, RCT (The Lancet, 2026)Effects of GLP-1 receptor agonists on alcohol consumption — systematic review and meta-analysis (eClinicalMedicine)Distilling the evidence for GLP-1 receptor agonists in alcohol use disorder (PMC)Liver fat / MASLD / MASH:Triple hormone receptor agonist retatrutide for MASLD — randomized phase 2a trial, Sanyal et al. (Nature Medicine, 2024) — PRIMARY SOURCE, cite this not secondary marketing sitesPhase 3 Trial of Semaglutide in MASH — ESSENCE trial (NEJM, 2024)Tirzepatide for MASH with Liver Fibrosis — SYNERGY-NASH trial (NEJM, 2024)Hyperglycemia / microvascular damage mechanism:Vascular complications of diabetes: A narrative review (Medicine journal)The Mechanism of Hyperglycemia-Induced Renal Cell Injury in Diabetic Nephropathy (PMC)Diabetes Mellitus and Neurovascular Pathology: Retinal and Brain Lesions review (PMC)Kidney:FLOW trial: Cardiovascular outcomes with semaglutide by severity of CKD in type 2 diabetes (PMC)Semaglutide Reduced Risk for Major Kidney Disease Events by 24% (American Diabetes Association)Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial (Nature Medicine)Sleep apnea:SURMOUNT-OSA: tirzepatide for OSA and obesity (ACC)Tirzepatide on OSA-related cardiometabolic risk — SURMOUNT-OSA secondary outcomes (Nature Medicine)Obstructive sleep apnea and cardiovascular disease — background risk stats (PMC)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700568/Lifestyle intervention / trial design:STEP 1 trial summary — lifestyle intervention design (Wiki Journal Club)Semaglutide and cardiovascular outcomes — SELECT trial design notes (Nature Medicine)Akkermansia:Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity (Dao et al., Gut, 2016...

Ancora nessuna recensione